{"id":292951,"date":"2024-02-10T00:00:00","date_gmt":"2024-02-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidid0066-biopharma-chronic-pain-epidemiology-asia-pacific\/"},"modified":"2026-03-31T10:31:01","modified_gmt":"2026-03-31T10:31:01","slug":"epidid0066-biopharma-hepatitis-b-virus-vaccine-epidemiology-asia-pacific","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidid0066-biopharma-hepatitis-b-virus-vaccine-epidemiology-asia-pacific\/","title":{"rendered":"Hepatitis B Virus Vaccine &#8211; Epidemiology &#8211; Asia-Pacific"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of the hepatitis B virus (<abbr data-abbreviation-entity=\"5636\" title=\"hepatitis B virus\">HBV<\/abbr>) vaccine comprises epidemiological estimates of key patient populations in the Asia-Pacific (Australia, Hong Kong, Taiwan, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Thailand, Vietnam). We report the population recommended to receive the <abbr data-abbreviation-entity=\"5636\" title=\"hepatitis B virus\">HBV<\/abbr> vaccine for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>All patient populations are forecast over a period of 20 years for the pharmaceutical markets in the Asia-Pacific.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr data-abbreviation-entity=\"5636\" title=\"hepatitis B virus\">HBV<\/abbr> vaccine forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the <abbr data-abbreviation-entity=\"5636\" title=\"hepatitis B virus\">HBV<\/abbr> vaccine-eligible population over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on Clarivate\u2019s Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS <\/span>Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts two <abbr data-abbreviation-entity=\"5636\" title=\"hepatitis B virus\">HBV<\/abbr> vaccine patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Vaccine-eligible population.<\/li>\n<li>Population newly eligible for the vaccine.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-292951","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-pain","biopharma-therapy-areas-hepatitis-b-virus","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/292951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/292951\/revisions"}],"predecessor-version":[{"id":293153,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/292951\/revisions\/293153"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=292951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}